- Rheumatologie-App Injektionstechnik
- Neue Studien
- Kongress Highlights
- EULAR 2019
- EULAR 2018
- EULAR 2017
- EULAR 2016
- EULAR 2015
- EULAR 2014
- ACR 2019
- ACR 2018
- ACR 2017
- ACR 2015
- ACR 2014
- Rheuma Top 2019
- Rheuma Top 2018
- Rheuma Top 2017
- Rheuma Top 2015
- Rheuma Top 2014
- Bilddatenbank
- RheumaTool
- SlideSet RA
- SlideSetSpA
- SonoTool
- FOCUS «Der Fuss»
- FOCUS «Die Hand»
- FOCUS «Kinderrheumatologie»
- EisenPaket
- LupusPaket
- OsteoPaket
- Publikationen
- Literaturservice
- Richtlinien
- Schmerzpaket
- Immunotalk
EULAR 2018 | Daily Highlights
Abatacept for SLE
A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT OR PLACEBO ON STANDARD OF CARE IN PATIENTS WITH ACTIVE CLASS III OR IV LUPUS NEPHRITIS
Abstract: OP0253
Authors: R. Furie et al.
Key content:
Intravenous abatacept (30 mg/kg for 3 months followed by 10 mg/kg every 4 weeks) was studied in a 24-month Phase III placebo controlled study in 405 patients with active proliferative lupus nephritis on background therapy with mycophenolate and glucocorticoids.
The study failed to demonstrate higher complete response rates after 1 year of abatacept treatment, but patients treated with abatacept had more rapid improvement in proteinuria and earlier, sustained complete responses. Improvements in SLE-related pharmacodynamic markers (C3, C4 and anti-dsDNA autoAb) were more sustained in ABA-treated pts.
Relevance:
Despite the fact that abatacept failed to meet the primary endpoint in this study, the results are promising and it could be interesting to study abatacept in SLE patients who have milder organ involvement and who not require or tolerate mycophenolate.
Zusammenfassung und Kommentar von:
Prof. Dr. Ulrich Walker
Basel
